The Global Health Body Sounds Warning Over Acute Scarcity of Obesity Jabs

Less than one in 10 individuals that would benefit from obesity jabs like Wegovy are able to get them, states the global health agency as it releases its first recommendations on the drugs.

Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.

Per projections, more than two billion will be living with obesity by 2030 without intervention.

"Our latest guidelines recognises that excess weight is a long-term condition that can be managed with thorough and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are key obstacles to widespread availability to the injections that can help people shift considerable body mass, explains the agency.

Weight-Loss Drug Shortage

Despite the present most optimistic case, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of those who need them, per the WHO.

The recommendation calls on countries and companies to widen access, via strategies including voluntary licensing.

Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.

How Obesity Jabs Operate

The injections replicate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so users consume fewer calories.

People usually start to lose weight within a few weeks of commencing the once-weekly jabs.

Studies suggests patients may see weight return within a year of discontinuing the medication, because their normal appetite return.

Being carrying excess weight elevates your likelihood for experiencing diseases, including diabetes, cardiovascular issues, stroke, and certain malignancies.

Excess weight affects individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.